← Back to Search
Eosinophilic Count As A Biomarker For Prognosis Of Melanoma Patients And Its Importance In The Response To Immunotherapy.
A. Moreira, W. Leisgang, G. Schuler, L. Heinzerling
Published 2017 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
AIM The prognostic role of eosinophils in cancer has been controversial. Some entities such as gastrointestinal cancers show a better survival, while others such as Hodgkin's lymphoma a worse survival in patients with eosinophilia. Patients who exhibited an increase in eosinophils upon therapy with ipilimumab or pembrolizumab were shown to survive longer. We wanted to investigate whether eosinophilia is a prognostic marker in metastatic melanoma. METHODS In total, 173 patients with metastatic melanoma from our data base (median age 60 years; n = 86 with immunotherapy, n = 87 without immunotherapy) were analyzed for eosinophil counts and survival over the course of 12 years. Eosinophilic count was detected by peripheral blood smear. The ethical committee had approved this retrospective study. RESULTS Melanoma patients with eosinophilia at any point in their course of disease show a trend toward longer survival independently of their therapy. There is a statistically significant difference for the patients who survive at least 12 months (p < 0.005). In patients with checkpoint inhibitor therapy, survival was significantly prolonged in every patient with eosinophilia (p < 0.05). Furthermore, 69% of the patients treated with immunotherapy experienced at least once an eosinophilia of 5% or greater compared with 46% in the immunotherapy naive-group; for an eosinophilia of 10% values were 30 and 9%, respectively. Interestingly, in patients with more than 20% eosinophils (n = 7) survival was prolonged with a median of 35 months (range 19-60 months) as compared with 16 months (range 1-117 months). CONCLUSION Eosinophilia is a prognostic marker in patients with metastatic melanoma.
This paper references
Significance of tumor associated tissue eosinophilia and other inflammatory cell infiltrate in early esophageal squamous cell carcinoma.
Y. Ohashi (2000)
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
M. Faries (2009)
Dendritic cell vaccination on the long run: 11-year survival in advanced melanoma patients is equivalent to ipilimumab-treatment
S Groß (2016)
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J. Brahmer (2010)
Granulocytes: Eosinophils enable the antitumour T cell response
K. Minton (2015)
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
E. Lipson (2015)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
Human Eosinophils Exert TNF-α and Granzyme A-Mediated Tumoricidal Activity toward Colon Carcinoma Cells
F. Legrand (2010)
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
A. Mackensen (2006)
Pivotal Advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response
S. Cormier (2006)
Identification of Innate IL-5–Producing Cells and Their Role in Lung Eosinophil Regulation and Antitumor Immunity
M. Ikutani (2012)
Regulation of Carcinogenesis by IL-5 and CCL11: A Potential Role for Eosinophils in Tumor Immune Surveillance1
L. Simson (2007)
Involvement of eosinophils in the anti-tumor response
S. Gatault (2012)
Murine hypodense eosinophils induce tumour cell apoptosis by a granzyme B-dependent mechanism
D. J. Costain (2001)
In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5
L. Rivoltini (1993)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Eosinophils and human cancer.
M. Samoszuk (1997)
Tumour-associated eosinophilia: a review.
D. Lowe (1981)
Melanoma and Lymphoma Rejection Associated With Eosinophil Infiltration Upon Intratumoral Injection of Dendritic and NK/LAK Cells
A. Capobianco (2008)
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
C. Gebhardt (2015)
Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice.
M. Samoszuk (2004)
Predictive immune markers in advanced melanoma patients treated with ipilimumab
V. Umansky (2016)
Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis
Jochen T Schaefer (2010)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
B. Weide (2016)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.
J. Delyon (2013)
Eosinophils in Cancer: Favourable or Unfavourable?
S. Sakkal (2016)
Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin‐2 (rhIL‐2) therapy
S. Rodgers (1994)
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors.
R. Lotfi (2007)
The appearance of hypodense eosinophils during interleukin-2 treatment.
J. Sedgwick (1990)
Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women’s Health Study
A. Prizment (2016)
Eosinophils and Cancer
B. Davis (2014)
Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells
R. Carretero (2015)
This paper is referenced by
Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report
M. Occhipinti (2018)
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
W. Ouwerkerk (2019)
Analysis of the immune status from peripheral whole blood with a single-tube multicolor flow cytometry assay.
Anna-Jasmina Donaubauer (2020)
Tumor Microenvironment: Hematopoietic Cells – Part B
A. Birbrair (2020)
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy.
J. Haanen (2020)
Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters.
I. Voutsadakis (2020)
One-Tube Multicolor Flow Cytometry Assay (OTMA) for Comprehensive Immunophenotyping of Peripheral Blood.
Anna-Jasmina Donaubauer (2019)
Exploring the role of atopy in non-atopic diseases
E. Hajdarbegovic (2017)
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
A. Filipović (2020)
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
F. Pagni (2019)
Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
C. E. Onesti (2018)
Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA
A. Moreira (2020)
Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy
Jia-Nan Cheng (2021)
Opposing roles of eosinophils in cancer
S. Simon (2018)
Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies
Y. Nakamura (2019)
Prognostic impact of eosinophils in peripheral blood and tumor site in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy
X. Yang (2021)
Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single‐centre analysis
T. Gambichler (2018)
New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer
K. Holub (2018)
Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy.
Y. Lou (2019)
AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer
E. Jensen-Jarolim (2018)
Eosinophils: The unsung heroes in cancer?
G. Varricchi (2018)
Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response.
F. Toussaint (2019)
Immune Modulatory Effects of Radiotherapy
B. Frey (2019)
Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles
Ihor O. Arkhypov (2020)
A new dawn for eosinophils in the tumour microenvironment
Sharon Grisaru-Tal (2020)
Case report of a patient with metastatic malignant melanoma treated with pembrolizumab
A. Fialova (2017)
Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report
M. Z. Temiz (2020)
The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer
Ryotaro Ohkuma (2021)
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
S. Simon (2020)
Biomarkers to predict prognosis and response to checkpoint inhibitors
T. Yuasa (2017)
CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
A. Kunert (2019)
Absolute and relative differential blood count predicts survival of AJCC stage I‐II melanoma patients scheduled for sentinel lymph node biopsy
N. B. Wagner (2020)See more